drugset / Trial / NCT06676579
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
Timeline
- Start
- 2025-06-09
- Primary completion
- 2028-03-02
- Completion
- 2029-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Avacopan | Small molecule | 30 mg | Oral |
| Comparator | Prednisolone | Other / unclassified | 0.2 mg/kg | — |
| Comparator | Prednisone | Other / unclassified | 0.4 mg/kg | — |
| Comparator | Methylprednisolone | Other / unclassified | 1 g | Intravenous |